Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, describes that although novel plasma biomarkers, such as amyloid and tau, have had good initial results in diagnosing Alzheimer’s disease in a laboratory setting but more research is required before they are used in a clinical setting. Dr Lukasewicz Ferreira highlights that one of the main issues was studies – including hers – using mainly white cohorts: studies with more diverse populations are crucial to see if factors like race and ethnicity influence biomarkers. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.
